SETD2 and neoplasm: Finally, we demonstrate not only that signaling through OXPHOS and mTORC1 is required for the proliferative benefit bestowed upon tumor cells following SETD2 inactivation, but that they also represent readily actionable therapeutic vulnerabilities for patients with SETD2-deficient tumors.